Fig. 6: Application in SARS-CoV-2 RBD-mRNA vaccine production.
From: Streamlined and on-demand preparation of mRNA products on a universal integrated platform

a A SARS-CoV-2 RBD-mRNA vaccine was constructed from optimized codons encoding the signal peptide (SP, 1–14 residues) and the receptor-binding ___domain (RBD, 319–541 residues) of the SARS-CoV-2 spike protein. b Electrophoresis image of RBD, where samples were loaded in the following order: marker, PCR products from the standard machine, PCR products from this platform, supernatant after magnetic bead capture by manual operation, and supernatant after magnetic bead capture by the platform. c RBD-mRNA synthesized and purified in vitro with the desired size quantified by an Agilent 2100 bioanalyzer system. d Western blotting analysis and (E) average relative density of SARS-CoV-2 RBD protein expression from mRNA-LNP produced on the proposed platform and PNI-prepared mRNA-LNP at 24 h post-transfection. PNI stands for Precision Nanosystems Ignite. The average relative density was assessed by gray analysis using ImageJ software